| Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy : results of SAKK 11/16, a phase IIa trial | Experimental hematology & oncology |  | | 2025 | 63 | 81 |
|
| A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors | Cancer research communications | | | 2024 | 112 | 212 |
|
| LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy | ESMO Congress 2023 | | | 2023 | 128 | 165 |
|
| Personalized immunotherapy with encapsulated cell technology : Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors | ESMO Congress 2022 | | | 2022 | 96 | 183 |
|
| Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites | Clinical Pharmacokinetics | | | 2018 | 741 | 910 |
|
| Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers | Basic & clinical pharmacology & toxicology | | | 2013 | 668 | 461 |
|
| The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro | British journal of pharmacology |  | | 2012 | 595 | 0 |
|
| Inhibiteurs des récepteurs plaquettaires P2Y12 à l'ADP: importance du métabolisme et influence des interactions médicamenteuses sur leurs paramètres pharmacocinétiques | | | | 2012 | 1,128 | 2,597 |
|
| Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients | Metabolism, clinical and experimental | | | 2011 | 695 | 0 |
|
| Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability | Current drug metabolism | | | 2010 | 679 | 0 |
|
